Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TCF1-LEF1 co-expression identifies a multipotent progenitor cell (TH2-MPP) across human allergic diseases.
Kratchmarov R, Djeddi S, Dunlap G, He W, Jia X, Burk CM, Ryan T, McGill A, Allegretti JR, Kataru RP, Mehrara BJ, Taylor EM, Agarwal S, Bhattacharyya N, Bergmark RW, Maxfield AZ, Lee S, Roditi R, Dwyer DF, Boyce JA, Buchheit KM, Laidlaw TM, Shreffler WG, Rao DA, Gutierrez-Arcelus M, Brennan PJ. Kratchmarov R, et al. Among authors: shreffler wg. Nat Immunol. 2024 May;25(5):902-915. doi: 10.1038/s41590-024-01803-2. Epub 2024 Apr 8. Nat Immunol. 2024. PMID: 38589618
Kinetics of basophil hyporesponsiveness during short-course peanut oral immunotherapy.
Kulis MD, Smeekens JM, Burk C, Yue X, Guo R, Orgel KA, Ye P, Herlihy L, Hamilton D, Li Q, Keet C, Shreffler W, Vickery BP, Burks AW, Kim EH. Kulis MD, et al. J Allergy Clin Immunol. 2022 Nov;150(5):1144-1153. doi: 10.1016/j.jaci.2022.05.020. Epub 2022 Jun 16. J Allergy Clin Immunol. 2022. PMID: 35716952 Free PMC article. Clinical Trial.
Breakthroughs in understanding and treating eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERs Symposium at the 2022 American Academy of Allergy, Asthma & Immunology Meeting.
Chehade M, Wright BL, Atkins D, Aceves SS, Ackerman SJ, Assa'ad AH, Bauer M, Collins MH, Commins SP, Davis CM, Dellon ES, Doerfler B, Gleich GJ, Gupta SK, Hill DA, Jensen ET, Katzka D, Kliewer K, Kodroff E, Kottyan LC, Kyle S, Muir AB, Pesek RD, Peterson K, Shreffler WG, Spergel JM, Strobel MJ, Wechsler J, Zimmermann N, Furuta GT, Rothenberg ME. Chehade M, et al. Among authors: shreffler wg. J Allergy Clin Immunol. 2023 Dec;152(6):1382-1393. doi: 10.1016/j.jaci.2023.08.021. Epub 2023 Sep 3. J Allergy Clin Immunol. 2023. PMID: 37660987 Review.
Who are the potential patients for omalizumab for food allergy?
Sampson HA, Bird JA, Fleischer D, Shreffler WG, Spergel JM. Sampson HA, et al. Among authors: shreffler wg. Ann Allergy Asthma Immunol. 2024 May;132(5):569-571. doi: 10.1016/j.anai.2024.03.006. Epub 2024 Mar 11. Ann Allergy Asthma Immunol. 2024. PMID: 38479711 No abstract available.
Omalizumab for the Treatment of Multiple Food Allergies.
Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS. Wood RA, et al. Among authors: shreffler wg. N Engl J Med. 2024 Mar 7;390(10):889-899. doi: 10.1056/NEJMoa2312382. Epub 2024 Feb 25. N Engl J Med. 2024. PMID: 38407394 Clinical Trial.
116 results